NOTICE: Many events listed here have been canceled or postponed due to the Covid-19 emergency. It is best to call ahead or check with organizer's websites to verify the status of any local event.

Change Location × Savannah, GA

    Recent Locations

      Cancer Biology and Immunotherapy in Savannah

      • Cancer Biology and Immunotherapy Photo #1
      • Cancer Biology and Immunotherapy Photo #2
      1 of 2
      March 30, 2020

      Monday   8:00 AM - 5:00 PM (daily for 3 times)

      15 East Liberty Savannah, GA United States
      Savannah, Georgia 31401

      • No Performers Listed
      Cancer Biology and Immunotherapy

      Cancer Biology and Immunotherapy
      About this Event
      About CBI-2020


      JanusJanus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. Ann Oncol 2012 Sep 23 (Suppl 8).

      About Cancer Biology and Immunotherpay-2020

      To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

      To this end, together with the United Scientific Group (USG) and under the auspices of the Mercer Medical School, Savannah Campus is organizing a Cancer Biology and Immunotherapy (CBI) meeting in Savannah, Georgia in March 30 to April 1, 2020. USG has successfully organized four Vaccine Research and Development meetings and during these events it has become apparent the cancer vaccine and immunotherapy research portions need to be expanded to their own conference.

      Cancer has clearly thwarted many treatment approaches, including oncogene-driven targeted agents, monoclonal antibodies, as well as immune-modulatory agents like interferons, lymphokines, and cytokines, and various anti-angiogenic agents. With this checkered past, one has to ask the hard questions: were the concepts incorrect or were the treatments used without a full understanding of the biology of the disease? Was a complete accounting made of the host-tumor interactions? Did we fully understand the complex mechanisms inherent to the tumor microenvironment, which could render many of these treatments ineffective?

      All too often pragmatic decisions, such as manufacturing requirements or financial decisions, have driven cancer R&D development and clinical trial design. Commercial strategy was crafted based on these limitations, such as ignoring early-stage or minimal residual disease patients to focus on late-stage or recurrent tumors which would achieve a clinical readout on a faster timescale. Furthermore, using cancer vaccines as a monotherapy in advanced disease patients, which flies in the face of the conventional tenets of vaccinology. Furthermore, targeting our treatments of various tumors while ignoring the magnitude and consequences of near limitless intra- and inter-tumoral genomic heterogeneity has been a major challenge. Also, in many cases, malignant progression is accompanied by major immune suppression. While successful treatments of passive immunotherapy are being heralded, the immune suppressive state of advanced disease is clinically limited. Possible combinatorial treatments of active and passive immunotherapy are warranted. These discussions will be topics of this first CBI meeting.

      Meeting Topics

      Cancer Pathology, tumor growth kinetics
      Cancer Metastasis
      Genomic Heterogeneity
      Among different patients
      Within Primary tumors
      Among cells that metastasize
      Within metastatic lesions
      Passive Immunotherapy
      Checkpoint inhibitors
      Tumor infiltrating lymphocytes
      Monoclonal Antibodies
      Laboratory and Industry production
      Immunotherapy beyond Checkpoint Inhibitors
      Host-Tumor Interactions
      Cancer Vaccines: Design and medical translation
      Active Specific Immunotherapy
      Patient selection for clinical trials: Advanced, Occult disease
      Adjuvants, development of biocompatible delivery systems
      Vaccine design and production technology
      Neoproteins and neoepitopes
      Cancer treatment monitoring and drug design
      Cancer Prevention
      Status Australian trials of HPV vaccine for Cervical Cancer

      Plenary Session Monday March 30, 2020

      8:30-9:00 Welcome and Introductions

      9:00 9:30 Dr. Olivera Finn: Immuno-Oncology: Understanding the Function and

      Dysfunction of the Immune System in Cancer.

      9:40-10:10 Professor J J O’leary: Cancer Pathology and tumor growth kinetics,

      Metastasis and tumor cell-stroma relationships.

      10:20-10:50 Dr. Heyu Ni: The role of blood platelets in tumorigenesis, metastasis,

      and tutor-associated thrombosis

      11:00-11:30 Dr. Julie Magarian Blander: Innate Immunity in Immunotherapy,

      Macrophages and Dendritic cells.

      11:40-12:10 Dr. Charles Swanton: Intratumor Heterogeneity: Evolution through

      Space and time.

      12-20-12:50 Dr. Michael Hwang: Mutations in oncogenes and tumor suppressor

      genes drive tumorigenesis: Translation for therapeutic purposes.

      12:50-2:00 Lunch

      2:00-2:30 Dr. Jason David Howard: Passive Immunotherapy in Advanced Disease

      Cancer Patients.

      2:40-5:30 Session 1. Passive Immunotherapy.

      Chairmen, Dr. Jason David Howard and Dr. Robert Dillman

      Plenary Session Tuesday March 31. 2020

      8:00-8:30 Dr. Shruti Naik, Two to Tango: Dialogue between Immunity and Stem

      Cells in Health and Disease.

      8:40-9:10 Dr. Keith Knutson, Immunotherapy beyond Checkpoint Inhibitors

      9:10-9:40 Dr. Robert Dillman, Cancer Vaccines: Evolution of Therapeutic


      10:00-10:15 Coffee Break

      10:15-10:45 Dr. Michael G. Hanna Jr., Personalized Cancer Vaccines: Design and

      Clinical application

      10:55-11:25 Dr. Vincent K. Tuohy. Primary Immunoprevention of Adult Onset


      11:35-12:35 Lunch

      12:35-3-30 Session 2. Active Specific Immunotherapy.

      Chairmen, Dr. Robert Dillman and Dr Vincent Tuohy

      3:30-5-30 Panel Discussion

      5:30-7:00 Refreshments, View Poster presentations and Cocktails

      Plenary Session Wednesday April 1, 2020

      8:30-9:00 Dr. Peter Nara, Precision Oncology-where are we and where are we to go.

      9:10-9:50 Dr. Martin D’sousa, Exploring nanoparticles as adjuvants in cancer


      10:00 -12:00 Session 3 Cancer treatment monitoring and drug design, Chairmen,

      Dr. Peter Nara and Dr. Martin D’Sousa.

      12:00-1:00 LUNCH

      1:00-1:30 Dr. David Hawkes, Cancer Prevention, HPV vaccine for Cervical Cancer

      1:40- 3:40 Plenary Session 4, Wednesday April 1, 2020 Cancer Prevention.

      Chairman, Dr. David Hawkes.

      Meeting Close or Panel Discussion 3:40 to 5:30.

      Possible Banquet sponsored by exhibitor.

      Plenary Speakers

      Michael Hwang

      Vogelstein Laboratory, JHMI

      Keith Knutson

      Mayo Clinic

      Charles Swanton

      University College London

      Heyu Ni

      University of Toronto, CA.

      Vincent K. Tuohy

      Cleveland Clinic, Lerner Research. Institute.

      David Hawkes

      Victorian Cytology Services

      John J. O’leary

      Trinity College. Dublin

      Julie Magarian Blander

      Weill Cornell Medicine The Jill Roberts Institute for Research in Inflammatory Bowel Disease

      Shruti Naik

      New York University School of Medicine

      Cost: $1,000

      Categories: Conferences & Tradeshows

      This event repeats daily for 3 times: Mar 30, Mar 31, Apr 1

      Event details may change at any time, always check with the event organizer when planning to attend this event or purchase tickets.